

TANAYA SHREE, MD PhD

shree@ohsu.edu

EDUCATION & TRAINING

Aug 2022 to present	Oregon Health and Sciences University Assistant Professor, Hematology & Medical Oncology and by courtesy, Department of Cell, Developmental and Cancer Biology Member, Knight Cancer Institute
Oct 2020 to Jul 2022	Stanford University Instructor, School of Medicine
Sept 2014 to Sept 2020	Stanford University Fellow in Hematology & Oncology, Translational Investigator Pathway
June 2012 to Sept 2014	Stanford University Resident in Internal Medicine, Translational Investigator Pathway
July 2004 to May 2012	Weill Cornell/Rockefeller/Sloan-Kettering Tri-Inst. MD-PhD Program PhD in Cancer Biology January 2011; MD awarded May 2012
Aug. 2000 to May 2004	Cornell University B. A. <i>cum laude</i> with academic distinction, Major in Biology

PUBLICATIONS

- Mentz M, Keay W, Strobl CD, Antonioli M, Adolph L, Heide M, Lechner A, Haebe S, Osterode E, Kridel R, Ziegenhain C, Wange LE, Hildebrand JA, **Shree T**, Silkenstedt E, Staiger AM, Ott G, Horn H, Szczepanowski M, Richter J, Levy R, Rosenwald A, Enard W, Zimmer-Strobl U, von Bergwelt-Baildon M, Hiddemann W, Klapper W, Schmidt-Supprian M, Rudelius M, Bararia D, Passerini V, Weigert O. (2022) PARP14 is a novel target in STAT6 mutant follicular lymphoma. *Leukemia*, doi: 10.1038/s41375-022-01641-x.
- Sagiv-Barfi I, Czerwinski DK, **Shree T**, Lohmeyer JJ, Levy R. (2022) Intratumoral immunotherapy relies on B and T cell collaboration. *Science Immunology*, 7(71):eabn5859
- Shree T**. (2022) Can B cell-deficient patients rely on COVID-19 vaccine-induced T cell immunity? *British Journal of Haematology*. 197(6):659-661.
- Shree T**, Shankar V, Lohmeyer JJK, Czerwinski DK, Schroers-Marin JG, Rodriguez GM, Beygi, S, Kanegai AM, Corbelli KS, Gabriel E, Kurtz DM, Khodadoust MS, Gupta NK, Maeda LS, Advani RH, Alizadeh AA, Levy R. (2022) CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. *Blood Cancer Discovery*. 3(2):95-102.
- Mooney KL, Czerwinski DK, **Shree T**, Frank MJ, Haebe S, Martin BA, Testa S, Levy R, Long SR. (2021) Serial FNA Allows Direct Sampling of Malignant and Infiltrating Immune Cells in Patients with B-cell Lymphoma Receiving Immunotherapy. *Cancer Cytopathology*. 130(3):231-237.

Haebe S*, **Shree T***, Sathe A, Day G, Czerwinski DK, Grimes S, Lee H, Martin B, Long SR, Ji HP, Levy R. (2021) Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma. *Blood*. 137(21):2869-2880. *Equal contribution.

Shree T, Li Q, Glaser SL, Brunson A, Maecker HT, Haile RW, Levy R, Keegan THM (2020). Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*, 38(15):1664-1675.

Khodadoust MS, Olsson N, Chen B, Sworder B, **Shree T**, Liu CL, Zhang L, Czerwinski DK, Davis MM, Levy R, Elias JE, Alizadeh AA (2019). B-cell lymphomas present immunoglobulin neoantigens. *Blood*, 133(8):878-881.

Shree T, Olson O, Elie BT, Kester JC, Garfall AM, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E and Joyce JA (2011). Macrophages and cathepsin proteases blunt chemotherapeutic response in metastatic breast cancer. *Genes & Development*, 25(23):2465-2479.

Elie B, Gocheva V, **Shree T**, Dalrymple SA, Holsinger L, Joyce JA (2010). Identification and preclinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. *Biochimie*, 92(11):1618-24.

Gocheva V, Wang HW, Gadea BB, **Shree T**, Garfall A, Hunter K, Berman T and Joyce JA (2010). IL-4 upregulates cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. *Genes & Development*, 24(3):241-55.

Hayley S, Crocker SJ, Smith PD, **Shree T**, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS (2004). Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. *Journal of Neuroscience*, 24(8):2045-53.

Ghahremani MH, Keramaris E, **Shree T**, Xia Z, Davis RJ, Flavell R, Slack RS, Park DS (2002). Interaction of the c-Jun/JNK pathway and cyclin-dependent kinases in death of embryonic cortical neurons evoked by DNA damage. *Journal of Biological Chemistry*, 277(38):35586-96.

SELECT ORAL PRESENTATIONS

Shree T, Haebe S, Sathe A, Day G, Czerwinski D, Lee HJ, Grimes S, Long S, Martin B, Ji HP, Levy R (Dec 2020). *Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing In Situ Vaccination*. Oral presentation at the Annual Meeting of the American Society of Hematology.

Shree T, Li Q, Brunson A, Glaser SL, Maecker HT, Haile RW, Levy R, Keegan THM (Jun 2019). *Impaired immune health in survivors of Diffuse Large B-cell Lymphoma (DLBCL): A Large Population-Based Study*. Oral presentation at the 15th International Conference on Malignant Lymphoma, Lugano, Switzerland. Chosen for the “Highlights of ICML” presentation at the end of the meeting.

Shree T, Khodadoust MS, Czerwinski D, Frank MJ, Hong WX, Greenstein R, Long S, Martin B, Levy R (Jun 2019). *A phase I/II trial of ibrutinib, intratumoral CpG and local low-dose radiation in patients with low-grade B-cell lymphoma: Interim Clinical and Correlative Results*. Oral presentation at the 15th International Conference on Malignant Lymphoma, Lugano, Switzerland.

Shree T, Khodadoust MS, Czerwinski D, Frank MJ, Hong WX, Greenstein R, Guo S, Long S, Martin B, Levy R (Mar 2019). *Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma*. Oral presentation at the Annual Meeting of the American Association for Cancer Research, Atlanta, GA.

Shree T, Li Q, Glaser SL, Maecker HT, Haile RW, Levy R, Keegan THM (Dec 2017). *Increased Incidence of Autoimmune and Infectious Diseases Among a Large Group of Diffuse Large B-cell Lymphoma*

(DLBCL) Survivors: a Population-based Study. Oral presentation at the Annual Meeting of the American Society of Hematology, Atlanta, GA.

Shree T, Elie B, Garfall A, Bell-McGuinn K, Simpson K, Barbashina V, Joyce JA (Oct 2009). *Simultaneous Targeting of Multiple Components of the Tumor Microenvironment.* Oral presentation at the 5th International Conference on Tumor Microenvironment: Progression, Therapy, & Prevention, Versailles, France.

INVITED SPEAKERSHIPS & LECTURES

Spring 2022 Guest Lecturer, HRP 253: Cancer Epidemiology and Prevention, Stanford University
 Sept 2021 Invited speaker, 'Ask the Doctor' Webinar on "Lymphoma and the Immune System", Lymphoma Research Foundation
 Winter 2019 Guest Lecturer, HRP 253: Cancer Epidemiology and Prevention, Stanford University
 Fall 2019 Guest Lecturer, BIOS 286: Single Cell Immunogenomics, Stanford University
 Mar 2018 Panelist, 18th Multidisciplinary Management of Cancers Meeting, Silverado, CA

CLINICAL TRIALS

A phase I/II single center, investigator-initiated, study of intra-tumoral mRNA-2752 in previously treated B cell lymphomas and cutaneous T cell lymphomas. PI: Dr. Ronald Levy. Roles: Sub-investigator, Protocol development. Pending.

Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination with BMS-986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies. PI: Dr. Saad Khan. Roles: Protocol author, Sub-investigator. Active.

Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination with BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas; PI: Dr. Ronald Levy. Roles: Sub-investigator, protocol author. Active.

Intratumoral Injection of SD-101, an Immunostimulatory CpG, in combination with Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma; PI: Dr. Ronald Levy. Roles: Sub-investigator. Active.

A Phase I/II, Dose-escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors; PI: Dr. Branimir Sikić. Roles: Sub-investigator. Completed.

A Phase 1/2, Non-Randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-Dose Radiation in Patients With Untreated Low-Grade B-cell Lymphoma; PI: Dr. Ronald Levy. Roles: Sub-investigator. Completed.

AWARDED GRANT FUNDING

2020-2025 NIH K08 Career Development Award
 2018-2020 American Cancer Society Postdoctoral Fellowship
 2017-2019 Parker Institute for Cancer Immunotherapy Postdoctoral Fellowship
 2017-2018 T32 training grant in Hematology
 2016-2019 Leukemia and Lymphoma Foundation, TRP grant (PI: R. Levy, prepared by T. Shree)

HONORS & AWARDS

2020 American Society of Hematology Abstract Achievement Award
 2020 Best Oral Presentation Award, Annual Stanford Hematology/Oncology Retreat
 2019 American Society of Hematology Abstract Achievement Award
 2019 Stanford Bio-X Interdisciplinary Sciences Institute Travel Award

2017	American Society of Hematology Abstract Achievement Award
2017	Selected for the Society of Translational Oncology's Fellows' Forum in October 2017
2012	The Franklyn Ellenbogen Prize in Hematology-Oncology, Weill Cornell Medical College
2010	Best poster award, Geoffrey Beene Cancer Research Conference
2007	Travel Award, Days of Molecular Medicine Meeting
2003	Inducted into the Sphinx Head Society at Cornell University
2003	Cornell Hughes Scholars Program Summer Fellowship
2002	Parkinson's Disease Foundation Student Summer Fellowship
2000-2004	Dean's List at Cornell University
2000-2004	Pauline and Irving Tanner Dean Scholar, Cornell University
2000	Valedictorian, Lisgar Collegiate Institute, Ottawa, Canada

MENTORING & ADVOCACY

2021-present	Research Career Accelerator Program, peer-to-peer mentoring
2019-present	Mentor, Women in Medicine Program, Stanford University School of Medicine
2019-2020	ResearchHERS campaign, American Cancer Society

RELEVANT COURSEWORK

Summer 2022	Advanced Course in Immunology (American Association of Immunologists)
Winter 2022	Academic Career Skills, Dana Farber Cancer Institute, NASDC program (NCI)
Fall 2021	STATS 366: Modern Statistics for Modern Biology, Stanford University; audited full course
Fall 2021	Cell & Gene Therapy Toolkit, University of Pennsylvania, NASDC program (NCI)
Jan-Dec 2021	Research Career Accelerator Program, Stanford Center for Clinical & Translational Research; Professional development course for early stage researchers

LICENSES, CERTIFICATIONS & PROFESSIONAL MEMBERSHIPS

Medical license, Oregon Medical Board, License #MD209990 (2022-present)
 Board certification, Medical Oncology, American Board of Internal Medicine (2019-present)
 Board certification, Internal Medicine, American Board of Internal Medicine (2015-present)
 Medical license, California Medical Board, License #A126589 (2012-present)
 American Society of Hematology
 American Society of Clinical Oncology
 American Association for Cancer Research
 Stanford Society for Physician Scientists